Tissue availability of insulin‐like growth factor I is inversely related to insulin resistance in essential hypertension: effects of angiotensin converting enzyme inhibition
Tissue availability of insulin‐like growth factor I is inversely related to insulin resistance in essential hypertension: effects of angiotensin converting enzyme inhibition
复制标题
胰岛素样生长因子 I 的组织可用性与原发性高血压的胰岛素抵抗呈负相关：血管紧张素转换酶抑制的影响
DOI：
10.1097/00004872-199816060-00018
复制
发表时间：
1998
影响因子：
4.9
通讯作者：
J. Díez
中科院分区：
文献类型：
--
作者：
C. Laviades;M. Gil;I. Monreal;Arantxa González;J. Díez
背景：胰岛素样生长因子I具有与胰岛素相似的生物学作用。该因子的组织通路取决于循环结合因子在其保留在血管内间隙内的结合蛋白3和能够穿过内皮的结合蛋白I之间的分布。初步结果表明，胰岛素样生长因子I的组织可利用性是高血压患者血糖调节的决定因素。目的探讨高血压患者循环中胰岛素样生长因子I的组织可利用度是否与胰岛素抵抗有关，以及慢性血管紧张素转换酶抑制是否影响该因子的组织可利用度和胰岛素抵抗。设计与方法研究29例高血压病患者和20例年龄匹配、性别匹配的正常血压受试者。在赖诺普利治疗12个月后，对25名患者进行重复测量。通过分析胰岛素样生长因子I在其结合蛋白3和1之间的分布，评估其在组织中的利用度。通过空腹胰岛素-葡萄糖相互作用的稳态模型分析，估计胰岛素抵抗指数。用放射免疫法测定血清胰岛素样生长因子I结合蛋白3和1、血浆胰岛素样生长因子I和胰岛素水平。结果高血压病患者基础胰岛素抵抗指数明显高于正常血压对照组。以正常血压人群的100%可信上限为分界点，12名高血压患者的胰岛素抵抗指数异常高。与胰岛素抵抗指数正常的患者相比，胰岛素抵抗指数高于正常的患者具有结合蛋白1水平降低、结合蛋白3水平相似、结合蛋白1/结合蛋白3比值降低、胰岛素样生长因子I水平相似的特点。高血压患者血清结合蛋白1水平及结合蛋白1/结合蛋白3比值与胰岛素抵抗指数呈负相关。赖诺普利治疗后胰岛素抵抗指数高于正常的高血压病患者胰岛素样生长因子I水平无明显变化，结合蛋白1水平和结合蛋白1/结合蛋白3比值显著升高，胰岛素样生长因子I水平恢复正常。其余患者的这些参数保持不变。结论这些结果提示循环胰岛素样生长因子I的组织可利用性是高血压患者胰岛素敏感性的一个决定因素。而胰岛素敏感性正常的患者表现出比正常组织获得更多的循环胰岛素样生长因子I，而胰岛素抵抗患者表现出正常的组织获得该因子。我们的发现表明，血管紧张素转换酶抑制剂恢复高血压患者胰岛素敏感性的能力可能与它们促进循环中胰岛素样生长因子I的组织可利用性有关。
Background The insulin-like growth factor I possesses biologic actions that resemble those of insulin. Tissue access of the factor depends on the distribution of the circulating bound factor between its binding protein 3 that remains within the intravascular space and its binding protein I that is able to cross the endothelium. Preliminary results have shown that tissue availability of insulin-like growth factor I is a determinant of glucose regulation in essential hypertension Objective To investigate whether the tissue availability of circulating insulin-like growth factor I in patients with essential hypertension is related to insulin resistance and whether chronic angiotensin converting enzyme inhibition influences tissue availability of the factor and insulin resistance in these patients. Design and methods We studied 29 patients with essential hypertension and 20 age-matched and sex-matched normotensive subjects. The measurements were repeated for 25 patients after 12 months of treatment with lisinopril. Tissue availability of circulating insulin-like growth factor I was assessed by analyzing its distribution between its binding proteins 3 and 1. An insulin resistance index was estimated using the homeostasis model analysis of fasting insulin–glucose interactions. Levels of serum insulin-like growth factor I binding proteins 3 and 1, plasma insulin-like growth factor I, and insulin were determined by specific radioimmunoassays. Results Baseline insulin resistance index was significantly higher in the hypertensive patients than it was in the normotensive controls. With the upper 100% confidence limit of the normotensive population as the cutoff point, a subgroup of 12 hypertensives had an abnormally high insulin resistance index. Compared with patients with normal insulin resistance indexes, patients with greater than normal indexes were characterized by lower binding protein 1 levels, similar binding protein 3 levels, lower binding protein 1: binding protein 3 ratio and similar insulin-like growth factor I levels. The serum binding protein 1 level and the binding protein 1: binding protein 3 ratio were inversely correlated to the insulin resistance index for the whole group of hypertensives. After treatment with lisinopril hypertensive patients with higher than normal insulin resistance indexes at baseline exhibited normalization of this parameter and significant increases of binding protein 1 levels and binding protein 1: binding protein 3 ratio, with no significant changes in insulin-like growth factor I levels. These parameters remained unchanged for the remaining patients. Conclusions These results suggest that tissue availability of circulating insulin-like growth factor I is a determinant of insulin sensitivity in patients with essential hypertension. Whereas the patients with normal insulin sensitivity exhibit greater than normal tissue access of circulating insulin-like growth factor I, patients with insulin resistance present normal tissue access of the factor. Our findings suggest that the ability of angiotensin converting enzyme inhibitors to restore insulin sensitivity in essential hypertensives may be related to their ability to facilitate the tissue availability of circulating insulin-like growth factor I.
登录
查看更多内容
胰岛素样生长因子 I (rhIGF-I) 作为高胰岛素血症胰岛素抵抗糖尿病的治疗剂。
影响因子：
5.1
作者：
Moses,AC;Morrow,LA;O'Brien,M;Moller,DE;Flier,JS
通讯作者：
Flier,JS
人类和灵长类动物肾上腺束状和肾小球的血管紧张素 II 受体：结合和类固醇生成的相关性。
DOI：
10.1016/0026-0495(84)90205-1
发表时间：
1984
期刊：
Metabolism: clinical and experimental
影响因子：
--
作者：
Douglas,JG;Brown,GP;White,C
通讯作者：
White,C
影响因子：
20.3
作者：
John I. Jones;D. Clemmons
通讯作者：
John I. Jones;D. Clemmons
影响因子：
8.3
作者：
James R. Sowers
通讯作者：
James R. Sowers
皮质醇会增加人体血浆胰岛素样生长因子结合蛋白-1。
DOI：
10.1530/acta.0.1280140
发表时间：
1993
期刊：
Acta endocrinologica
影响因子：
--
作者：
Conover,CA;Divertie,GD;Lee,PD
通讯作者：
Lee,PD